Table 2.

Univariate analysis of intracranial control and overall survival by patient and tumor characteristics

	Intracranial Control		Overall Survival
Variable	Hazard Ratio (95% CI)	P-value	Hazard Ratio (95% CI)	P-value
Histology
Mixed vs Embryonal	1.04 (0.24–4.44)	0.96	0.65 (0.16–2.72)	0.55
Mixed vs Choriocarcinoma	0.65 (0.22–1.89)	0.43	0.57 (0.21–1.50)	0.25
Mixed vs Yolk Sac	0.83 (0.11–6.23)	0.85	0.49 (0.07–3.60)	0.48
Primary tumor site
Testicular vs Mediastinal	2.23 (1.00–4.98)	0.05	1.85 (0.91–3.77)	0.09
Timing of brain metastases
At relapse vs Diagnosis	0.8 (0.37–1.72)	0.57	0.71 (0.35–1.44)	0.34
Number of brain metastases
1 vs 2–5	2.47 (0.83–7.41)	0.11	2.36 (0.96–5.80)	0.06
1 vs >5	5.09 (1.65–15.67)	0.005	5.19 (1.98–13.62)	0.001
Systemic disease in the lungs
No vs Yes	1.29 (0.60–2.80)	0.52	1.93 (0.99–3.77)	0.05
Systemic disease in the liver
No vs Yes	1.06 (0.50–2.23)	0.89	1.39 (0.73–2.64)	0.32
Systemic disease in the bone
No vs Yes	1.26 (0.30–5.31)	0.76	5.38 (2.41–12.01)	<0.0001
Surgery of brain metastases
No vs Yes	0.97 (0.44–2.16)	0.95	0.92 (0.47–1.82)	0.81
Chemotherapy at time of brain metastases
No vs Yes	1.04 (0.48–2.27)	0.91	0.84 (0.45–1.58)	0.59
Chemotherapy timing
Before RT vs concurrent with RT	0.95 (0.34–2.62)	0.92	0.70 (0.31–1.59)	0.39
Before RT vs after RT	0.90 (0.31–2.61)	0.85	0.87 (0.40–1.88)	0.72
Radiation fields
WBRT or SRS vs Combination	0.24 (0.06–1.00)	0.05	0.38 (0.14–1.08)	0.07
Radiation dose (BED, continuous)	0.90 (0.86–0.96)	<0.0001	0.91 (0.88–0.95)	<0.0001
Steroids during radiation
No vs Yes	5.30 (1.50–16.90)	0.009	3.03 (1.25–7.33)	0.01